Table of Contents
Epigral Limited is an integrated chemical manufacturer with a strong presence across the chlor-alkali value chain and a growing portfolio of downstream derivatives and specialty chemicals. The company manufactures Caustic Soda, Chloromethanes, Epichlorohydrin (ECH), CPVC Resin, Hydrogen Peroxide, Caustic Potash, and Chlorotoluenes, serving more than 15 downstream industries, including construction, water treatment, pharmaceuticals, agrochemicals, paints, textiles, and other industrial applications. Epigral is undergoing a structural transformation from a chloralkali-led commodity chemical manufacturer into an integrated, downstream-focused chemical platform, with derivatives and specialty chemicals contributing ~52% of revenue in FY26 and targeted to reach ~70% by FY28. A key element of this strategy is increasing the conversion of captive chlorine into higher-value downstream products, with captive chlorine consumption targeted to rise from ~75% currently to 90-95% by FY28, thereby improving value capture, reducing exposure to commodity-cycle volatility and supporting better capital efficiency. The company’s principal growth platforms are Epichlorohydrin (ECH), CPVC Resin and Chlorotoluenes, supported by significant capacity additions. ECH capacity is expanding from 50 KTPA to 100 KTPA, while CPVC Resin capacity is doubling from 75 KTPA to 150 KTPA. In addition, the recently commissioned 15 KTPA Chlorotoluene facility is expected to scale up meaningfully from FY27, providing exposure to higher-value applications and import-substitution opportunities. ECH remains a key growth driver, supported by healthy utilization and applications across epoxy resins, pharmaceuticals, and industrial segments, while CPVC provides exposure to structural demand from plumbing, water management, and infrastructure. The company’s backward integration, captive power infrastructure and integrated manufacturing ecosystem provide greater control over key inputs and support cost competitiveness across the value chain. Beyond the existing expansion programme, Epigral has also established a 100-acre land bank at Dahej to support future chemistry development, with management evaluating additional import-substitution opportunities across products with attractive demand growth and return potential. Overall, Epigral’s investment proposition centres on greater downstream integration, increased contribution from value-added products, capacity-led growth, and improved earnings diversification, which should progressively reduce its dependence on the chloralkali cycle and strengthen its positioning as an integrated, more value-added chemical manufacturer.
Why do we need to invest in Epigral Ltd
Accelerating shift toward high-value specialty derivatives to drive structural rerating
Epigral is undergoing a strategic transformation from a predominantly Chlor-Alkali-led manufacturer toward an integrated, downstream-focused chemical platform, with increasing emphasis on higher-value derivatives and specialty chemicals. Captive chlorine consumption rose to ~75% in FY26, enabling the company to convert more chlorine internally into higher-value products and reduce exposure to merchant chlorine sales and commodity-cycle volatility. Management is targeting >70% contribution from derivatives and specialty chemicals by FY28, supported by significant capacity expansion across Epichlorohydrin (ECH), CPVC Resin and Chlorotoluenes. ECH capacity is being expanded from 50 KTPA to 100 KTPA, while CPVC Resin capacity is being scaled from 75 KTPA to 150 KTPA, alongside a 15 KTPA Chlorotoluenes facility to deepen the downstream value chain further. The increasing downstream integration should progressively improve product mix and reduce the company’s dependence on the chlor-alkali cycle. Its ECH, manufactured through a bio-based glycerine route, caters to diverse end-use industries, including epoxy resins, water treatment, automotive, pharmaceuticals, and infrastructure, while CPVC Resin is positioned to benefit from structural demand across plumbing, fire-safety, and industrial applications. The planned Chlorotoluenes value chain further increases the company’s exposure to higher-value pharmaceutical and agrochemical intermediates, while offering an opportunity to capitalize on domestic import-substitution demand. With Rs. 451 crore of capital work-in-progress as of FY26-end, largely related to CPVC, ECH and other expansion projects, near-term financial performance may remain impacted by commissioning-related costs and the gradual ramp-up of new capacities. However, as expanded capacities progressively stabilize, higher downstream contribution, improved asset utilization, and operating leverage should support revenue growth and capital efficiency. Overall, the combination of downstream integration, rising contribution from higher-value derivatives, capacity-led growth and import-substitution opportunities provides a credible pathway toward stronger growth visibility and a more resilient business profile, with lower sensitivity to the cyclicality of the Chlor-Alkali business.
Epoxy resin creates new downstream growth engines and deepens value-chain integration
Epigral is entering the next phase of its downstream integration strategy with the proposed 100 KTPA Epoxy Resin & Formulations facility, which could become an important incremental growth engine beyond its existing Chlor-Alkaline businesses. The epoxy resin opportunity represents a natural forward-integration step, leveraging Epigral’s established ECH platform, as ECH is a key raw material in epoxy resin manufacturing. The company’s integrated position is further strengthened by its ability to manufacture high-purity, bio-based ECH using glycerin as feedstock. The company is simultaneously doubling ECH capacity from 50 KTPA to 100 KTPA, with the expanded capacity expected to strengthen its position as India’s largest ECH facility. ECH demand is diversified across epoxy resins, wind energy, automotive components, adhesives, infrastructure, pharmaceuticals and water-treatment chemicals, providing multiple structural demand drivers for the expanded platform. Against this backdrop, moving further downstream into epoxy resin and formulations can enable Epigral to capture a larger portion of the value chain rather than remaining primarily an ECH supplier. The Epoxy resin and formulations facility therefore has strategic relevance beyond its incremental capacity. The domestic epoxy market, estimated at around 2.5-3.0 lakh tonnes, presents a sizeable addressable opportunity, supported by diverse end-use applications across wind-turbine blades, automotive, construction, coatings and industrial segments. The increasing deployment of renewable-energy infrastructure and continued investments in construction and manufacturing provide structural demand visibility for epoxy-based products. Notably, Epigral’s existing ECH integration provides a natural feedstock advantage, allowing the company to internalize part of the ECH-to-epoxy value chain and potentially improve overall value capture from its chlorine-based manufacturing ecosystem. The proposed epoxy projects also provide Epigral with an opportunity to diversify its earnings profile through greater export exposure, with management identifying Europe as a potential target market. European capacity rationalization and elevated production costs could create export opportunities for cost-competitive Indian manufacturers. Epigral’s glycerin based ECH manufacturing route, integrated production infrastructure and expanding downstream portfolio provide a potential competitive advantage in addressing such export opportunities. Overall, the epoxy projects mark an important evolution in company’s growth strategy, shifting from capacity expansion across existing product categories toward deeper downstream integration, higher value capture, and the development of a broader specialty chemical portfolio. This transition could progressively reduce reliance on commodity-led earnings and create additional avenues for sustainable growth.
CPVC expansion to drive forward integration and strengthen earnings growth
Epigral’s CPVC business is emerging as a key growth engine in its broader strategy to shift from a predominantly Chlor-Alkali-led business to a more integrated, downstream-focused chemical portfolio. CPVC represents a natural forward-integration opportunity for the company, as its integrated manufacturing complex enables captive consumption of chlorine, thereby converting a commodity-oriented intermediate into a higher-value downstream product. The company currently has 75 KTPA of CPVC resin capacity and is expanding this to 150 KTPA, with commercialization targeted for Q2FY27. Following the expansion, Epigral expects to become one of the world’s largest CPVC resin manufacturers, providing significant incremental capacity to support the structural growth of the domestic CPVC market. CPVC demand is expected to remain supported by infrastructure spending, housing and real-estate development, plumbing upgrades and the gradual shift toward durable, corrosion-resistant piping solutions. With Indian CPVC demand projected to grow at around 13% CAGR, rising penetration provides a structural growth opportunity over the medium term. Against this backdrop, the company is expanding capacity in an established and growing market, leveraging its existing CPVC manufacturing and operating platform. As CPVC capacity scales up, higher volumes of internally generated chlorine can be directed toward downstream derivatives, strengthening utilization of Epigral’s integrated complex and reducing reliance on merchant chlorine sales. This deeper downstream integration should enhance supply stability and cost efficiency while enabling the company to capture greater value from chlorine through successive stages of value addition. Epigral has already established a 75 KTPA CPVC Resin platform, supported by operating experience, an existing customer base and established market presence. The incremental capacity of 75KTPA therefore builds on an existing CPVC franchise and manufacturing platform, enabling a phased ramp-up while leveraging the company’s existing capabilities and customer relationships. With the company also present across CPVC Resin and Compound, the expansion further strengthens its position across the CPVC value chain. Near-term CPVC performance, however, has been volatile due to customer inventory behaviour and fluctuations in the PVC market. During Q1FY27, management indicated that CPVC growth was below earlier expectations as customers remained cautious on inventory amid PVC price fluctuations, while the monsoon season also affected demand. Management expects Q3 and Q4 to remain the stronger CPVC demand periods and anticipates improved volumes through the year. Overall, the CPVC expansion strengthens Epigral’s downstream integration strategy by combining capacity-led volume growth, structural domestic demand, captive chlorine utilization and higher value added downstream product.
Strong balance sheet and disciplined capital allocation support the expansion cycle
Epigral enters its next investment cycle with a relatively healthy financial position, giving it enough flexibility to fund downstream expansion without undue pressure on the balance sheet. With net debt/EBITDA at 1.0x in FY26 and 0.8x in Q1FY27, the company remains comfortably leveraged despite ongoing capex, supporting its phased expansion across ECH, CPVC, Chlorotoluenes and multipurpose chemicals. This strategy is expected to gradually increase the contribution of value-added products and improve earnings quality, while reducing reliance on large-scale commodity capacity additions. The company has delivered a strong long-term growth track record, with revenue and PAT CAGR of ~20% and ~17%, respectively, over FY16-26; however, FY26 revenue remained broadly flat at Rs. 2,527 crore as weaker chlor-alkali realizations offset continued growth in derivatives. We expect growth to re-accelerate, with revenue estimated to grow at ~16.1% CAGR over FY26-28E, supported by the ramp-up of CPVC and ECH capacities and expansion of the chlorotoluene value chain, driving higher utilization, downstream integration and revenue contribution. EBITDA margin is expected to moderate from the FY25 peak of 27.9% amid capacity ramp-up and softer chlor-alkali realizations. PAT is expected to decline modestly, with higher interest costs from expansion-related borrowings partly offsetting operating leverage. Importantly, the capex cycle is expected to transition toward stronger cash generation, with planned capex of ~Rs. 740 crores during FY26-28E supporting the company’s next phase of growth. Strong operating cash flows are expected to fund a meaningful portion of the expansion internally, limiting reliance on external funding and preserving balance-sheet flexibility. Consequently, net debt/EBITDA is expected to improve as cash generation outpaces incremental borrowings, while RoE and RoCE are expected to recover, as asset utilization improves, chlorine integration deepens, and operating leverage emerges. Overall, moderate leverage, improving free cash flow, disciplined capital deployment, and a rising contribution from downstream derivatives provide a supportive foundation for earnings and return-ratio recovery as the current expansion cycle matures.
Valuation & Outlook
Epigral is transitioning from a chlor-alkali-led chemical manufacturer toward an integrated, downstream-focused specialty chemicals platform, leveraging its captive chlorine, hydrogen and power infrastructure at Dahej to progressively shift the product mix toward higher-value derivatives. The company’s downstream portfolio spans CPVC resin, ECH, chlorotoluenes and other specialty chemicals, which should enable greater value capture from its integrated chlorine chain and reduce earnings sensitivity to chlor-alkali cyclicality. While FY26 operating performance remained subdued amid weak chemical realizations, lower utilization and elevated input costs, the company has delivered a 20%/14%/17% revenue/EBITDA/PAT CAGR over FY16-26, while maintaining a comfortable net debt/EBITDA of 1.0x. The key earnings catalyst is the ramp-up of the ongoing CPVC and ECH expansions, which will double capacities to 150 KTPA and 100 KTPA, respectively. These additions are expected to support volume growth, improve utilization of the integrated chlorine chain and increase captive consumption, thereby enhancing downstream value capture. The shift in business mix is already visible, with derivatives and specialty products contributing 52% of FY26 revenue versus 45% in FY24, while management is targeting a contribution of ~70% by FY28. This mix improvement should gradually reduce the company’s dependence on commodity chlor-alkali products and improve earnings quality. The growth runway is further supported by the planned Rs. 600 crores investment in epoxy resin and formulations facility and a multipurpose plant. The projects are strategically aligned with Epigral’s existing ECH and chlor-alkali integration, with more than 50% of epoxy raw-material value expected to be sourced internally. Management expects the two projects to generate peak revenue of ~Rs. 1,300-1,500 crores, providing an additional downstream growth opportunity across epoxy resins and specialty intermediates. With the CPVC and ECH expansions nearing commissioning and the epoxy/MPP projects providing a longer-term growth pipeline, Epigral is positioned for a gradual improvement in capacity utilization, operating leverage and product mix. Consequently, the medium-term earnings outlook should increasingly reflect the contribution from higher-value downstream products and normalized utilization rather than the weaker FY26 operating environment. We, thus, valued Epigral Ltd at 14x FY28E EPS, implying a Target Price of Rs 1,182 per share, offering a potential upside of 19.2% from current levels over a one-year horizon.
